Interestingly, IL-6 targeting by antibodies was found to induce synergistic T cell killing effects when combined with T cell immunoglobulin and mucin-domain containing-3, also known as HAVCR2 receptor (TIM-3/ HAVCR2) therapy, in animal cancer models [77]. The gene discussed is HAVCR2; the disease is cancer.